Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial

Table 1

Prescribed treatment based on patients/tumor characteristics.

Treatment modulation	Patient/tumor characteristics
Higher dose (70.2 Gy) to the tumor bed	(i) Positive resection margin; (ii) Perineural infiltration; (iii) Postoperative PSA > 0.2 ng/mL
ENI	(i) pN1; (ii) Lymph node risk > 15%* and <10 resected lymph nodes; (iii) Gleason score > 7
Short-term (6 months) AHT	(i) pT > 2; (ii) Gleason score = 7
Long-term (24 months) AHT	(i) pN1; (ii) Preoperative PSA > 20 ng/mL; (iii) Gleason score > 7

∗Based on Roach 3rd [22]. ENI: elective nodal irradiation; AHT: adjuvant hormonal therapy.